Anti-cancer medical group:
1. Wuzhong, Jiangsu: Wu Traditional Chinese Medicine, a holding subsidiary, is currently carrying out the project of "R&D and industrialization of recombinant human endostatin injection, a national first-class biological anticancer drug", which is in the stage of applying for phase III clinical research and has independent intellectual property rights. In 2006, it was supported by the national "863" project of non-small cell lung cancer. 20 10, 1 1, the pulp with scientific and technological achievements in Jiangsu province.
2. Haixin Co., Ltd.: independently developed a national first-class new drug named "antigen sensitized human dendritic cells (APDC)", which can be used to treat rectal cancer. Haixin Biotechnology Co., Ltd. (holding 565,438+0% of the shares) cooperated with Shanghai Second Military Medical University to develop a national first-class drug, which was the first drug independently developed in China and officially approved by the State Food and Drug Administration (SFDA) for APDC of advanced colorectal cancer. The 2009 annual report shows that the third phase of clinical practice has passed the expert demonstration organized by the State Administration of Pharmaceutical Products and is under examination and approval. Through hard work, the enterprise has obtained nearly 5 million yuan from the national "major new drug creation" fund.
3. Yatai Group: Invest in the pharmaceutical industry-the company takes biological vaccines and anti-tumor drugs as the development direction of new products, and has formed a series of anti-cancer products mainly based on "Shenyi Capsule" and anti-cancer biological missiles. At the same time, new anticancer drugs such as interleukin-1 1 and ginsenoside Rg3 injection have been reserved.
4. Shuanglu Pharmaceutical Co., Ltd.: The company was selected as one of the key cultivation enterprises in "Beijing Biomedical Industry Leaping Development Project" and the first batch of "10000 Project" in Zhongguancun National Independent Innovation Demonstration Zone. The company has reserved a number of superior varieties with market potential at home and abroad in the fields of tumor treatment, anti-inflammatory and analgesic, cardiovascular and cerebrovascular diseases and liver diseases, and strives to introduce more than three antibodies and vaccine drugs. Constantly cultivate heavy varieties in the field of liver disease treatment, and strive to become an important enterprise in the field of liver disease treatment in China. The company's main products, such as recombinant human granulocyte colony stimulating factor, interleukin-1 1, asparaginase and anti-tumor products, are gradually entering the markets of Eastern Europe, Asia and South America.
5. Tetracyclic organism: The company's main products include recombinant human interleukin-2 (used for comprehensive treatment of malignant tumors such as kidney cancer and malignant melanoma), recombinant human interleukin-2 injection, recombinant human granulocyte stimulating factor injection and recombinant human erythropoietin injection, among which recombinant human interleukin-2 for injection is an industrialized genetic engineering product of the national project "Development, pilot production and clinical application of genetically engineered human interleukin -2"; Beijing Sihuan Biopharmaceutical, which still holds 55% of the shares, is the earliest enterprise engaged in the research and development and production of genetic engineering drugs and diagnostic reagents in China. Its proprietary technology includes sublingual buccal tablets such as interleukin -2 (used to treat liver cancer), interferon, EPO and G-CSF.